The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients
Abstract
Introduction: After initial treatment, differentiated thyroid cancer (DTC) patients are stratified as low and high risk based on clinical/pathological features. Recently, a risk stratification based on additional clinical data accumulated during follow-up has been proposed. Objective: To evaluate the predictive value of delayed risk stratification (DRS) obtained at the time of the first diagnostic control (8–12 months after initial treatment). Methods: We reviewed 512 patients with DTC whose risk assessment was initially defined according to the American (ATA) and European Thyroid Association (ETA) guidelines. At the time of the first control, 8–12 months after initial treatment, patients were re-stratified according to their clinical status: DRS. Results: Using DRS, about 50% of ATA/ETA intermediate/high-risk patients moved to DRS low-risk category, while about 10% of ATA/ETA low-risk patients moved to DRS high-risk category. The ability of the DRS to predict the final outcome was superior to that of ATA and ETA. Positive and negative predictive values for both ATA (39.2 and 90.6% respectively) and ETA (38.4 and 91.3% respectively) were significantly lower than that observed with the DRS (72.8 and 96.3% respectively,P<0.05). The observed variance in predicting final outcome was 25.4% for ATA, 19.1% for ETA, and 62.1% for DRS. Conclusions: Delaying the risk stratification of DTC patients at a time when the response to surgery and radioiodine ablation is evident allows to better define individual risk and to better modulate the subsequent follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationLong-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Self-citationHAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
Natural History, Treatment, and Course of Papillary Thyroid Carcinoma*
DEGROOT, L. J., KAPLAN, E. L., MCCORMICK, M., & STRAUS, F. H. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-414 · Cited by 1,049
Tuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., Fagin, J. A., & Shaha, A. (2010) · Thyroid · doi:10.1089/thy.2010.0178 · Cited by 924
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma
Tubiana, M., Schlumberger, M., Rougier, P., Laplanche, A., Benhamou, E., Gardet, P., Caillou, B., Travagli, J.-P., & Parmentier, C. (1985) · Cancer · doi:10.1002/1097-0142(19850215)55:4<794::aid-cncr2820550418>3.0.co;2-z · Cited by 573
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group
Byar, D. P., Green, S. B., Dor, P., Williams, E. D., Colon, J., van Gilse, H. A., Mayer, M., Sylvester, R. J., & Van Glabbeke, M. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90291-3 · Cited by 554
Follow up Approaches in Thyroid Cancer: A Risk Adapted Paradigm
Tuttle, R. M., & Leboeuf, R. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.02.008 · Cited by 122
Verburg, F. A., Stokkel, M. P. M., Dueren, C., Verkooijen, R. B. T., Mäder, U., van Isselt, J. W., Marlowe, R. J., Smit, J. W. A., Reiners, C., & Luster, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1315-6 · Cited by 111
Risk-Adapted Management of Thyroid Cancer
Tuttle, R. M. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.764 · Cited by 99
Application of the Predictive Value Model in the Analysis of Test Effectiveness
Galen, R. S. (1982) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)31007-2 · Cited by 77
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCabanillas, M. E., McFadden, D. G., & Durante, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30172-6 · Cited by 1,430
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Metadata
- Authors
- Castagna, M. G., Maino, F., Cipri, C., Belardini, V., Theodoropoulou, A., Cevenini, G., & Pacini, F.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09
- Volume
- 165
- Issue
- 3
- Pages
- 441-446
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2110829017
- Cited by
- 275
- References
- 13
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.